AZOL COMPOUNDS REPLACED WITH AMIDA
Argentina Patent
Stats

Importance

AR Family Size
|
Non-US Coverage
|
Abstract
Amide substituted azol compounds which are inhibitors of TNKS1 and / or TNKS2, methods for preparing said compounds, intermediates useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and use of said compounds to manufacture a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a single agent or in combination with other active ingredients. Claim 1: A compound characterized in that it is of formula (1) wherein: X¹ represents NR³ or O; X² represents a CR⁶ or N; R¹ represents a group selected from: -OR⁹, and -N (R¹⁰) R¹¹; R² represents a group selected from: hydrogen, C₁₋₃-alkyl, and C₃₋₄-cycloalkyl; R³ represents a hydrogen atom; R⁴ represents a hydrogen atom; R⁵ represents a group selected from: hydrogen, C₁₋₃-alkyl, C₁₋₃-alkoxy, C₁₋₃-haloalkyl, C₁₋₃-haloalkoxy, and halogen; R⁶ represents a group selected from: hydrogen, and halogen; R⁷ represents a hydrogen atom; R⁸ represents a group selected from: aryl, and heteroaryl, where the aryl and heteroaryl groups are optionally substituted with one, two or three substituents, which are independently selected from each other from: C₁₋₆-alkyl, C₁₋₃-alkoxy , C₃₋₆-cycloalkyl, C₃₋₆-cycloalkoxyl, C₁₋₃-haloalkyl, C₁₋₃-haloalkoxy, halogen, cyano, nitro, hydroxyl, (C₁₋₆-alkyl) -S-, (C₁₋₆-alkyl ) -S (= O) -, (C₁₋₆-alkyl) -S (= O) ₂-, -S (= O) (= NR¹⁵R¹⁶), -N (R¹⁰) R¹¹, R¹⁰ (R¹¹) N- ( C₁₋₆-alkyl), R¹⁰ (R¹¹) N- (C₂₋₆-alkoxy) -, phenyl, phenoxy, -N (R¹²) C (= O) R¹³, -C (= O) OH, -C (= O) OR⁹, and -C (= O) N (R¹²) ₂, where two substituents of said aryl group, if they are in ortho position with each other, can be joined together so as to form together metandiylbisoxil, ethan-1,2 -diylbisoxy, propan-1,3-diyl, or butan-1,4-diyl; R⁹ represents a group selected from: C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₁₋₆-hydroxyalkyl, and (C₁₋₃-alkoxy) - (C₁₋₆-alkyl); R¹⁰ and R¹¹ are independently selected from each other from: hydrogen, C₁₋₆-alkyl, C₃₋₆-cycloalkyl, (C₃₋₆-cycloalkyl) - (C₁₋₆-alkyl), C₂₋₆-hydroxyalkyl, (C₁ ₋₃-alkoxy) - (C₂₋₆-alkyl), C₁₋₆-haloalkyl, H₂N- (C₂₋₆-alkyl), (C₁₋₃-alkyl) N (H) (C₂₋₆-alkyl), ( C₁₋₃-alkyl) ₂N (C₂₋₆-alkyl), HOC (= O) - (C₁₋₆ alkyl), R⁹OC (= O) - (C₁₋₆-alkyl), 4-6 membered heterocycloalkyl, ( 4-6 membered heterocycloalkyl) - (C₂₋₆-alkyl), aryl, heteroaryl, aryl- (C₁₋₆-alkyl), and heteroaryl- (C₁₋₆-alkyl), where the 4-6 membered heterocycloalkyl groups they are optionally substituted with one or two substituents, which are independently selected from each other from: C₁₋₃-alkyl, C₁₋₃-haloalkyl, C₁₋₃-alkoxy, C₁₋₃-haloalkoxy, C₃₋₄-cycloalkyl, C₃ ₋₄-cycloalkoxy, amino, hydroxyl, a halogen atom, and cyano, and, d Where aryl and heteroaryl groups are optionally substituted with one or two substituents, which are independently selected from each other from: C₁₋₃-alkyl, C₃₋₆-cycloalkyl, C₁₋₃-alkoxy, C₃₋₆-cycloalkoxyl, C₁ ₋₃-haloalkyl, C₁₋₃-haloalkoxy, halogen, cyano, -C (= O) OH, -C (= O) OR⁹, and -C (= O) N (R¹²) ₂, or, R¹⁰ and R¹¹ together with the nitrogen atom to which they are attached they form a 4-6 membered heterocycloalkyl group, wherein a carbon atom is optionally replaced by a group containing additional heteroatom selected from NR¹⁴, O, S, S (= O) and S (= O) ₂ where in the heterocycloalkyl group an additional ring atom is optionally replaced by C (= O), where said 4-6 membered heterocycloalkyl group is optionally substituted with one or two substituents, which are independently selected from yes between: C₁₋₃-alkyl, C₁₋₃-haloalkyl, C₁₋₃-alkoxy, C₁₋₃ -haloalkoxy, C₃₋₄-cycloalkyl, C₃₋₄-cycloalkoxy, amino, hydroxyl, a halogen atom, and cyano, or R¹⁰ and R¹¹ together with the nitrogen atom to which they are attached form a group selected from: the group of formulas (2) where * indicates the point of union of said group with the rest of the molecule; R¹² represents a group selected from: hydrogen, and C₁₋₃-alkyl; R¹³ represents a group selected from: hydrogen, C₁₋₆-alkyl, C₁₋₆-hydroxyalkyl, C₃₋₆-cycloalkyl, C₁₋₆-haloalkyl, (C₁₋₃-alkoxy) - (C₁₋₆-alkyl), aryl , and heteroaryl, where the aryl and heteroaryl groups are optionally substituted with one or two substituents, which are independently selected from each other from: C₁₋₃-alkyl, C₃₋₆-cycloalkyl, C₁₋₃-alkoxy, C₃₋₆ -cycloalkoxy, C₁₋₃-haloalkyl, C₁₋₃-haloalkoxy, halogen, cyano, and hydroxyl; R¹⁴ represents a group selected from: hydrogen, C₁₋₃-alkyl, C₁₋₃-haloalkyl, and C₃₋₄-cycloalkyl; R¹⁵ represents a group selected from: hydrogen, cyano, (C₁₋₃-alkyl) -C (= O) -, and (C₁₋₃-haloalkyl) -C (= O) -; R¹⁶ represents a group selected from: C₁₋₄-alkyl, and C₃₋₄-cycloalkyl; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture thereof. Claim 22: A compound characterized in that it is of the general formula (3), wherein X¹ represents N, and X², R², R⁵ and R⁸ are as defined for the compound of the general formula (1) according to any of the claims 1 to 6. Claim 23: A compound characterized in that it is of the general formula (4), wherein X², R⁵ and R⁸ are as defined for the compound of the general formula (1) according to any one of claims 1 to 6 Claim 24: A compound characterized in that it is of the general formula (5), wherein X¹ represents N, and R¹ and R² are as defined for the compound of the general formula (1) according to any one of claims 1 to 6 Claim 25: A compound characterized in that it is of the general formula (6), wherein X¹ represents N; R¹⁷ represents OR¹⁸; R¹⁸ represents hydrogen or phenyl; and R² is as defined for the compound of general formula (1) according to any one of claims 1 to 6. Claim 26: A compound characterized in that it is of general formula (7), wherein X¹ represents NR³; R¹⁷ represents OR¹⁸; R¹⁸ represents hydrogen or phenyl; and X², R², R³, R⁵ and R⁸ are as defined for the compound of general formula (1) according to any one of claims 1 to 6.

First Claim
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Country Designations

Patent Owner(s)
Patent Owner | Address |
---|---|
BAYER PHARMA AG | DELEVERKUSEN GERMANY LEVERKUSEN NORTH RHINE-WESTPHALIA |
International Classification(s)

- [Classification Symbol]
- [Patents Count]
Inventor(s)
Inventor Name | Address |
---|---|
PHILIP DR LIENAU | DE |
SIMON DR HOLTON | DE |
KNUT DR EIS | DE |
JENS DR ACKERSTAFF | DE |
DETLEV DR SLZLE | DE |
STEFAN DR GOLZ | DE |
PHILIPP DR BUCHGRABER | DE |
VOLKHART MIN DR LI | DE |
DANIEL DR BASTING | DE |
FRANZISKA DR SIEGEL | DE |
MARCUS DR BAUSER | DE |
JZSEF BALINT | DE |
MICHAELA DR BAIRLEIN | DE |
NINGSHU DR LIU | DE |
ECKHARD JIAN - DR BENDER | DE |
SARAH WAGNER | ALT-STRALAU 52/53 DE |
Cited Art Landscape
- No Cited Art to Display

Full Text

Legal Events

Matter Detail

Renewals Detail

Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:

Add to additional portfolios:

Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement

Recipient Email Address

Recipient Email Address

Comment
Recipient Email Address

Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
Important Notes on Latency of Status data
This Status indicator is an estimation based on the relevant document kind code. As such, it status will only indicate "Published" or "Granted". Expired, lapsed or abandoned statuses are not available in this release. Please refer to the legal status information for more information.
This status should not be taken as legal conclusion. No representations are made as to the accuracy of the status provided. Please consult a legal professional before relying on this status information.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
Only for Granted EP cases
EP validations represent the countries in which the EP patent may be in force. Data is based on reporting from the various EP contracting states. The reporting consistency can vary across the countries.